Selective effects of PD-1 on Akt and ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation

Science Signaling

Volumn 5, Issue 230, 2012, Pages

  Patsoukis, Nikolaos ^a   Brown, Julia ^a   Petkova, Victoria ^a   Liu, Fang ^b   Li, Lequn ^a   Boussiotis, Vassiliki A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKINE; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; RAS PROTEIN; RETINOBLASTOMA PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; SMAD3 PROTEIN; TRANSCRIPTION FACTOR E2F; UBIQUITIN PROTEIN LIGASE; CDC25A PROTEIN, HUMAN; IL2 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; S PHASE KINASE ASSOCIATED PROTEIN; SMAD3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL CYCLE G1 PHASE; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; CYTOLOGY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CDC25 PHOSPHATASES; CELL CYCLE CHECKPOINTS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; G1 PHASE; HUMANS; INTERLEUKIN-2; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RETINOBLASTOMA PROTEIN; S-PHASE KINASE-ASSOCIATED PROTEINS; SMAD3 PROTEIN; TRANSCRIPTION, GENETIC;

EID: 84863089861     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2002796     Document Type: Article

References (74)

1. L. S. Walker, A. K. Abbas, The enemy within: Keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2, 11-19 (2002).
2. L. Li, V. A. Boussiotis, Physiologic regulation of central and peripheral T cell tolerance: Lessons for therapeutic applications. J. Mol. Med. 84, 887-899 (2006).
3. L. M. Francisco, P. T. Sage, A. H. Sharpe, The PD-1 pathway in tolerance and auto-immunity. Immunol. Rev. 236, 219-242 (2010).
4. + T cell responses to antigen in lymph nodes and tissues. J. Immunol. 179, 5064-5070 (2007).
5. + T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6, 280-286 (2005).
6. E. D. Reynoso, K. G. Elpek, L. Francisco, R. Bronson, A. Bellemare-Pelletier, A. H. Sharpe, G. J. Freeman, S. J. Turley, Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J. Immunol. 182, 2102-2112 (2009).
7. M. E. Keir, S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M. Koulmanda, G. J. Freeman, M. H. Sayegh, A. H. Sharpe, Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203, 883-895 (2006).
8. L. M. Francisco, V. H. Salinas, K. E. Brown, V. K. Vanguri, G. J. Freeman, V. K. Kuchroo, A. H. Sharpe, PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015-3029 (2009).
9. C. Blank, T. F. Gajewski, A. Mackensen, Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy. Cancer Immunol. Immunother. 54, 307-314 (2005).
10. A. J. Currie, A. Prosser, A. McDonnell, A. L. Cleaver, B. W. Robinson, G. J. Freeman, R. G. van der Most, Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: Regulation and counterregulation. J. Immunol. 183, 7898-7908 (2009).
11. D. M. Kuang, Q. Zhao, C. Peng, J. Xu, J. P. Zhang, C. Wu, L. Zheng, Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327-1337 (2009).
12. L. Zhang, T. F. Gajewski, J. Kline, PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114, 1545-1552 (2009).
13. + T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202 (2006).
14. T. Watanabe, A. Bertoletti, T. A. Tanoto, PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J. Viral Hepat. 17, 453-458 (2010).
15. C. Petrovas, J. P. Casazza, J. M. Brenchley, D. A. Price, E. Gostick, W. C. Adams, M. L. Precopio, T. Schacker, M. Roederer, D. C. Douek, R. A. Koup, PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203, 2281-2292 (2006).
16. C. L. Day, D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E.W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, Z. Mncube, J. Duraiswamy, B. Zhu, Q. Eichbaum, M. Altfeld, E. J. Wherry, H. M. Coovadia, P. J. Goulder, P. Klenerman, R. Ahmed, G. J. Freeman, B. D. Walker, PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
17. C. J. Sherr, J. M. Roberts, Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18, 2699-2711 (2004).
18. I. Matsuura, N. G. Denissova, G. Wang, D. He, J. Long, F. Liu, Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430, 226-231 (2004).
19. R. Boutros, C. Dozier, B. Ducommun, The when and wheres of CDC25 phosphatases. Curr. Opin. Cell Biol. 18, 185-191 (2006).
20. F. Bennett, D. Luxenberg, V. Ling, I. M. Wang, K. Marquette, D. Lowe, N. Khan, G. Veldman, K. A. Jacobs, V. E. Valge-Archer, M. Collins, B. M. Carreno, Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J. Immunol. 170, 711-718 (2003).
21. kip1 to degradation. Cell Cycle 5, 2123-2129 (2006).
22. kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 168, 2729-2736 (2002).
23. L. J. Appleman, A. Berezovskaya, I. Grass, V. A. Boussiotis, CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J. Immunol. 164, 144-151 (2000).
24. kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 6, 290-297 (2000).
25. J. H. Kehrl, L. M. Wakefield, A. B. Roberts, S. Jakowlew, M. Alvarez-Mon, R. Derynck, M. B. Sporn, A. S. Fauci, Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163, 1037-1050 (1986).
26. L. Gorelik, R. A. Flavell, Transforming growth factor-b in T-cell biology. Nat. Rev. Immunol. 2, 46-53 (2002).
27. J. Massagué, How cells read TGF-b signals. Nat. Rev. Mol. Cell Biol. 1, 169-178 (2000).
28. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382, 325-331 (1996).
29. Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18, 1571-1583 (1999).
30. A. C. Carrano, E. Eytan, A. Hershko, M. Pagano, SPK2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1, 193-199 (1999).
31. Kip1. Genes Dev. 11, 1464-1478 (1997).
32. A. Alessandrini, D. S. Chiaur, M. Pagano, Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11, 342-345 (1997).
33. H. Morisaki, A. Fujimoto, A. Ando, Y. Nagata, K. Ikeda, M. Nakanishi, Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (Cdk) inhibitor by cyclin E/Cdk2. Biochem. Biophys. Res. Commun. 240, 386-390 (1997).
34. Kip1. EMBO J. 16, 5334-5344 (1997).
35. L. J. C. Jonk, S. Itoh, C. H. Heldin, P. ten Dijke, W. Kruijer, Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-β, activin, and bone morphogenetic protein-inducible enhancer. J. Biol. Chem. 273, 21145-21152 (1998).
36. I. Reynisdóttir, K. Polyak, A. Iavarone, J. Massagué, Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9, 1831-1845 (1995).
37. A. Iavarone, J. Massagué, Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature 387, 417-422 (1997).
38. A. Iavarone, J. Massagué, E2F and histone deacetylase mediate transforming growth factor β repression of cdc25A during keratinocyte cell cycle arrest. Mol. Cell. Biol. 19, 916-922 (1999).
39. E. Vigo, H. Muller, E. Prosperini, G. Hateboer, P. Cartwright, M. C. Moroni, K. Helin, CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol. Cell. Biol. 19, 6379-6395 (1999).
40. D. Ray, Y. Terao, D. Nimbalkar, L. H. Chu, M. Donzelli, T. Tsutsui, X. Zou, A. K. Ghosh, J. Varga, G. F. Draetta, H. Kiyokawa, Transforming growth factor β facilitates β-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol. Cell. Biol. 25, 3338-3347 (2005).
41. β-TRCPlinks Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 17, 3062-3074 (2003).
42. 0 T cells. J. Immunol. 158, 5642-5648 (1997).
43. + T cells. Science 271, 1276-1278 (1996).
44. R. V. Parry, J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, J. L. Riley, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543-9553 (2005).
45. T. F. Franke, S. I. Yang, T. O. Chan, K. Datta, A. Kazlauskas, D. K. Morrison, D. R. Kaplan, P. N. Tsichlis, The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81, 727-736 (1995).
46. B. M. Burgering, P. J. Coffer, Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376, 599-602 (1995).
47. D. R. Alessi, M. Andjelkovic, B. Caudwell, P. Cron, N. Morrice, P. Cohen, B. A. Hemmings, Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15, 6541-6551 (1996).
48. Y. Latchman, C. R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. Iwai, A. J. Long, J. A. Brown, R. Nunes, E. A. Greenfield, K. Bourque, V. A. Boussiotis, L. L. Carter, B. M. Carreno, N. Malenkovich, H. Nishimura, T. Okazaki, T. Honjo, A. H. Sharpe, G. J. Freeman, PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261-268 (2001).
49. G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, H. F. Horton, L. Fouser, L. Carter, V. Ling, M. R. Bowman, B. M. Carreno, M. Collins, C. R. Wood, T. Honjo, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
50. +T cells and is overcome by IL-2. Eur. J. Immunol. 32, 634-643 (2002).
51. + T cell anergy in vivo. J. Immunol. 182, 6682-6689 (2009).
52. ras proteins in normal human T lymphocytes. J. Immunol. 148, 2417-2422 (1992).
53. B. C. Turner, N. K. Tonks, U. R. Rapp, J. C. Reed, Interleukin 2 regulates Raf-1 kinase activity through a tyrosine phosphorylation-dependent mechanism in a T-cell line. Proc. Natl. Acad. Sci. U.S.A. 90, 5544-5548 (1993).
54. P. E. Kovanen, W. J. Leonard, Cytokines and immunodeficiency diseases: Critical roles of the gc-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 202, 67-83 (2004).
55. T. S. Migone, S. Rodig, N. A. Cacalano, M. Berg, R. D. Schreiber, W. J. Leonard, Functional cooperation of the interleukin-2 receptor b chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation. Mol. Cell. Biol. 18, 6416-6422 (1998).
56. B. Remillard, R. Petrillo, W. Maslinski, M. Tsudo, T. B. Strom, L. Cantley, L. Varticovski, Interleukin-2 receptor regulates activation of phosphatidylinositol 3-kinase. J. Biol. Chem. 266, 14167-14170 (1991).
57. J. D. Powell, C. G. Lerner, R. H. Schwartz, Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J. Immunol. 162, 2775-2784 (1999).
58. A. D. Wells, M. C. Walsh, D. Sankaran, L. A. Turka, T cell effector function and anergy avoidance are quantitatively linked to cell division. J. Immunol. 165, 2432-2443 (2000).
59. Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat. Immunol. 7, 1157-1165 (2006).
60. kip1 is required for transplantation tolerance induced by costimulatory blockade. J. Immunol. 177, 5169-5176 (2006).
61. H. Gille, M. Kortenjann, O. Thomae, C. Moomaw, C. Slaughter, M. H. Cobb, P. E. Shaw, ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J. 14, 951-962 (1995).
62. S. Chu, T. J. Ferro, Sp1: Regulation of gene expression by phosphorylation. Gene 348, 1-11 (2005).
63. C. R. Chen, Y. Kang, P. M. Siegel, J. Massagué, E2F4/5 and p107 as Smad cofactors linking the TGFβ receptor to c-myc repression. Cell 110, 19-32 (2002).
64. M. Donzelli, M. Squatrito, D. Ganoth, A. Hershko, M. Pagano, G. F. Draetta, Dual mode of degradation of Cdc25 A phosphatase. EMBO J. 21, 4875-4884 (2002).
65. M. Donzelli, G. F. Draetta, Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 4, 671-677 (2003).
66. M. Donzelli, L. Busino, M. Chiesa, D. Ganoth, A. Hershko, G. F. Draetta, Hierarchical order of phosphorylation events commits Cdc25A to βTrCP-dependent degradation. Cell Cycle 3, 469-471 (2004).
67. L. Busino, M. Donzelli, M. Chiesa, D. Guardavaccaro, D. Ganoth, N. V. Dorrello, A. Hershko, M. Pagano, G. F. Draetta, Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature 426, 87-91 (2003).
68. J. Falck, N. Mailand, R. G. Syljuasen, J. Bartek, J. Lukas, The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847 (2001).
69. C. S. Sørensen, R. G. Syljuåsen, J. Falck, T. Schroeder, L. Rönnstrand, K. K. Khanna, B. B. Zhou, J. Bartek, J. Lukas, Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3, 247-258 (2003).
70. I. Hassepass, R. Voit, I. Hoffmann, Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint. J. Biol. Chem. 278, 29824-29829 (2003).
71. A. R. Khaled, D. V. Bulavin, C. Kittipatarin, W. Q. Li, M. Alvarez, K. Kim, H. A. Young, A. J. Fornace, S. K. Durum, Cytokine-driven cell cycling is mediated through Cdc25A. J. Cell Biol. 169, 755-763 (2005).
72. Kip1. Eur. J. Immunol. 33, 1988-1997 (2003).
73. J. M. Chemnitz, R. V. Parry, K. E. Nichols, C. H. June, J. L. Riley, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945-954 (2004).
74. D. Tzachanis, G. J. Freeman, N. Hirano, A. A. van Puijenbroek, M.W. Delfs, A. Berezovskaya, L. M. Nadler, V. A. Boussiotis, Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat. Immunol. 2, 1174-1182 (2001).